Frankfurt - Delayed Quote EUR

Ascletis Pharma Inc. (2VJ.F)

0.7500

0.0000

(0.00%)

At close: May 9 at 3:29:02 PM GMT+2

Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On Obesity (ECO 2025) in Malaga, Spain.

PR Newswire 3 days ago

ASCLF
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today positive topline results of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study (NCT06680440), conducted in the U.S., of ASC30 oral once-daily tablet in participants with obesity (body mass index (BMI): 30-40 kg/m2). The Phase Ib MAD study consisted of three cohorts, each with a different weekly titration scheme, for a total of four-week treatment and one-week follow up. Scheme 1 (mid starting

PR Newswire 17 days ago

ASCLF
Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces positive interim results from its randomized, double-blind, placebo-controlled Phase Ib single subcutaneous (SQ) injection study (NCT06679959), conducted in the U.S., of small molecule ASC30 with three ultra-long-acting SQ injection formulations in patients with obesity (body mass index (BMI): 30-40 kg/m2).

PR Newswire last month

ASCLF
Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces it will host an Obesity Portfolio Webinar on April 2, 2025, from 9:00 a.m. – 10:30 a.m. ET.

PR Newswire last month

ASCLF
Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies in Australia in healthy subjects with elevated low-density lipoprotein cholesterol (LDL-C) (Part I) and in patients with obesity (Part II) (NCT06427590).

PR Newswire last month

ASCLF
Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today positive interim results from the first two cohorts of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study (NCT06680440), conducted in the U.S., of ASC30 oral once-daily tablet in patients with obesity (body mass index (BMI): 30-40 kg/m2). The Phase Ib MAD study consists of 3 cohorts, with eight patients in each cohort on ASC30 tablets and two patients in each cohort on matching placebo. Cohort

PR Newswire 2 months ago

ASCLF
Ascletis Pharma’s ASC30 oral tablet shows promise in obesity trial

Up to 60 hours of long half-life and dose-proportional PK were demonstrated by the tablet.

Clinical Trials Arena 3 months ago

ASCLF
Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today positive topline results from its U.S. single ascending dose (SAD) study (NCT06680440) of ASC30 oral tablet in patients with obesity (body mass index (BMI): 30-40 kg/m2). The SAD study consists of five cohorts (2 mg, 5 mg, 10 mg, 20 mg and 40 mg) with a total of 40 patients with obesity under fasting conditions.

PR Newswire 3 months ago

ASCLF
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging efficacy results from its study in diet-induced obese (DIO) mice combining ASC47, a first-in-class muscle-preserving weight loss drug candidate for the treatment of obesity, with semaglutide.

PR Newswire 4 months ago

ASCLF
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) once-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024.

PR Newswire 5 months ago

ASCLF
Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces topline results of its Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) for its first-in-class, muscle-preserving weight loss drug candidate, ASC47 for the treatment of obesity.

PR Newswire 5 months ago

ASCLF
Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today completion of initial dosing in its two recently initiated U.S. Phase I clinical trials for ASC30, the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once monthly subcutaneously and once-daily orally for the treatment of obesity. Ascletis received clearance for its Investigational New Drug (IND) applications from the U.S. Food and Drug Administration (FDA) in July 2024 for ASC30 tablets and September 20

PR Newswire 7 months ago

ASCLF
Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024

Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672, "Ascletis") dedicated to the research and development and commercialization of new drugs in the field of metabolic dysfunction-associated steatohepatitis (MASH), today announced a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024, held June 5-8, 2024 in Milan, Italy. A copy of the poster is available under the Posters/Publications page of Gannex's website a

PR Newswire 10 months ago

ASCLF

Performance Overview

Return	2VJ.F	HANG SENG INDEX (^HSI)
YTD	+118.02%	+14.00%
1-Year	+390.20%	+23.36%
3-Year	+74.42%	+14.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ascletis Pharma Inc. (2VJ.F)

Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025

Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

Ascletis Pharma’s ASC30 oral tablet shows promise in obesity trial

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity

Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024

Performance Overview